Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer

Yoshihiro Kakeji, Eiji Oki, Akinori Egashira, Noriaki Sadanaga, Ikuo Takahashi, Masaru Morita, Yasunori Emi, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

19 引用 (Scopus)

抜粋

Objective: This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer. Methods: Patients with measurable advanced or recurrent gastric cancer and no prior exposure to the investigational drugs were treated with intravenous docetaxel 35 mg/m2 on days 1 and 15, and oral S-1 80 mg/m 2/day on days 1-14 every 4 weeks. The primary endpoint was objective response. Results: Thirty-five eligible patients were enrolled and received a total of 151 cycles of treatment (median 3, range 1-19). One complete response and 13 partial responses were observed, with an overall response rate of 40% (95% CI: 24-56%). Median progression-free survival and median overall survival times were 4.5 and 14.2 months, respectively. The most common grade 3-4 toxicities were neutropenia (23%) and leukocytopenia (15%). Conclusion: Biweekly docetaxel combined with S-1 is active in advanced or recurrent gastric cancer, and can be administered with proper management of adverse events in an outpatient clinic.

元の言語英語
ページ(範囲)49-52
ページ数4
ジャーナルOncology
77
発行部数1
DOI
出版物ステータス出版済み - 7 1 2009

    フィンガープリント

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Kakeji, Y., Oki, E., Egashira, A., Sadanaga, N., Takahashi, I., Morita, M., ... Maehara, Y. (2009). Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Oncology, 77(1), 49-52. https://doi.org/10.1159/000226111